Media Coverage header image

Media Coverage

Advanced Search
  • 01182023
    Birmingham Business Journal

    Pack Health, a Quest Diagnostics company, has unveiled plans to nearly double the space of its headquarters in Birmingham and add at least 200 full-time employee positions. The project is based on economic development incentives from the state of Alabama in recognition of the public benefits accruing from the expansion of Pack Health's landmark Birmingham facility.

  • 01112023
    360Dx

    In a wide-ranging presentation at the 41st Annual JP Morgan Healthcare Conference, Quest Diagnostics' new President and CEO Jim Davis addressed multiple segments of the business, including Quest's hospital and physician laboratory market, advanced diagnostics, and the growing consumer-initiated testing (CIT) efforts.

  • 01032023
    Employee Benefits News

    Quest Diagnostics workforce drug testing data showed that nearly one in 10 (9.7%) post-accident drug tests was positive for a drug — underscoring the considerable role drug use plays in workforce accidents. The most troubling aspect of the Quest data was the finding that positivity for marijuana in 2021 was 63% higher in post-accident testing than pre-employment testing, suggesting some individuals who pass pre-employment screens use the drug post-hire.

  • 12202022
    Miami Herald

    There’s a trio of viruses spreading in the U.S. — COVID-19, the flu and RSV — and some in the medical world are calling it a “tripledemic.” If you’re feeling sick, it can be tough to differentiate among COVID-19, the flu and RSV because they share similar symptoms and can also look like the common cold. With COVID-19 and the flu, the CDC reports that “you cannot tell the difference between” the pair based on symptoms. Luckily, there is a test that can detect whether you have COVID-19, the flu and even RSV that you can get through a health care provider. Options include a test made by Labcorp and another created by Quest Diagnostics.

  • 12192022
    Bloomberg

    There’s no simple way to tell who has Alzheimer’s disease, but with a blockbuster treatment for millions of Americans on the horizon, blood-test makers are gearing up to change this. Even doctors who were initially skeptical about blood tests for the condition are gaining confidence that products from Quest Diagnostics Inc., Quanterix Corp. and C2N Diagnostics can help distinguish which patients may qualify for treatment with the experimental drug lecanemab, expected to be approved next year.

  • 12162022
    Eat This, Not That!

    Flu season continues to dominate national headlines as cases rise and hospitals are overcrowded. As a result of a spike in influenza cases, hospitals are feeling the pressure. "The strain that this is putting on our healthcare system is certainly a concern," Dr. Hema Kapoor, Infectious Diseases and Immunology with Quest Diagnostics tells us. "The overlap that we're seeing with other viruses has also put additional stress on the system. Pediatric hospitals have been overwhelmed by patients with RSV, and while the CDC noted it appears transmission was slowing in areas of the country, we've been seeing an increase in hospitalizations due to flu and COVID-19."

  • 12092022
    360Dx

    Quest Diagnostics said Thursday that it has formed a strategic laboratory collaboration with Maine healthcare system Northern Light Health. Under the agreement, Quest will acquire select assets of Northern Light's outreach laboratory business, named Northern Light Laboratory, in an all-cash transaction and will provide management services for nine of the system's hospital labs, as well as its cancer center laboratory at Northern Light Cancer Care in Brewer, Maine.

  • 12012022
    Lab Pulse

    Quest Diagnostics on Thursday announced a group purchasing agreement for its laboratory stewardship solution with Premier, a healthcare company uniting an alliance of hospitals, health systems, and providers.

  • 11302022
    HR.com

    Human resource executives and other C-Suite leaders are grappling with unprecedented strain caused by “The Great Resignation” wage inflation and, more recently, concerns about a potential future recession. Never has the challenge of keeping employees healthy, safe and engaged been more fraught. While these complex issues elude an easy fix, a recent survey from Quest Diagnostics suggests HR executives are overlooking the retention power of a perk they already provide: health benefits. According to 1,269 HR executives and employees surveyed, 36% of employees who were thinking of leaving their jobs cited a desire for better healthcare benefits as a top reason.

  • 11282022
    NJBIZ

    Quest Diagnostics announced Nov. 28 that it completed its acquisition of LabCare Plus, the outreach laboratory services business of Ohio-based Summa Health.

  • 11222022
    Managed Healthcare Executive

    Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, talks about why shortening this gap is critical to ensuring better patient outcomes and shared steps hospitals, health systems and physicians can take now to reduce testing delays, improve outcomes and lower costs of care.

  • 11172022
    The Washington Post

    During the last 15 years, researchers have become increasingly interested in developing blood tests that provide a window into the brain. Today, three tests — by C2N Diagnostics, Quest Diagnostics and Quanterix — are on the market, with more on the way. C2N debuted a test two years ago based on discoveries by Washington University scientists. Tests by Quest and Quanterix entered the market this year. None is covered by Medicare. Other companies, including Eli Lilly and Roche, have developed tests or are working on them. Next-generation tests are on the way. C2N charges $1,250 for its test and offers financial assistance for eligible patients. Quest, which charges $500, said some health plans are paying for the test. Quanterix declined to disclose a price but said its test is much cheaper than specialized scans. All the companies are trying to secure broader insurance coverage.

  • 11142022
    Clinical Lab Products

    Continued staffing shortages, more industry consolidation, and the growing ubiquity of at-home testing are just a few of the predictions that clinical laboratory experts are making for 2023. CLP recently asked clinical laboratory industry experts to weigh in on their predictions for the coming year. Following, in no particular order, are the top 10 predictions for 2023.

  • 11112022
    Healthline

    “There is room for error, particularly with at-home testing,” Dr. Jeffrey Dlott, senior medical director of diagnostics services at Quest Diagnostics, told Healthline. “Drawing one’s own blood can be daunting and anxiety-ridden for many. And if it’s not done right, results can be inconclusive and require the collection process to be repeated. For many, a blood draw by a trained phlebotomist may be preferred over pricking one’s own finger at home.”

  • 11042022
    MedTech Dive

    Quest Diagnostics is broadening access to its multiplex test to detect flu and COVID-19, letting patients self-collect samples for the test at its 1,600 testing centers across the U.S. Previously, patients had to make an appointment at a testing site, where they were swabbed by a clinician.

  • 11012022
    ROI-NJ

    Jim Davis, who helped lead the Quest Diagnostics response to the COVID-19 pandemic, officially assumed the role of CEO and president Tuesday morning, succeeding the retiring Steve Rusckowski. Davis also was elected to the company’s board of directors. Davis, who came to Quest in 2013 as senior vice president of diagnostics solutions, has served as executive vice president for general diagnostics since 2017.

  • 10272022
    HR Dive

    Employers are in the business of supporting employee health. According to the Society for Human Resource Management’s 2022 Employer Benefits Survey, nearly half of employers consider wellness benefits a significantly important offering. But striking the balance between helping employees without overreaching into employee privacy can be tricky. HR Dive spoke with Steven Goldberg, MD, MBA, vice president and chief health officer, employee and population health, at Quest Diagnostics about how the company has managed efforts directed at employee health — while also respecting worker privacy.

  • 10252022
    Fast Company

    Leading brands are well-oiled marketing machines. You can’t become a household name without it. But a select subset of brands are taking that expertise and the size of their platforms, and using them to bring awareness to important issues or raise money for critical causes.

    QUEST FOR HEALTH EQUITY: As a brand most Americans only think about when they’re getting their blood drawn or urine tested, Quest Diagnostics moved to play a larger role in addressing health disparities in underserved communities when it established Quest for Health Equity at the end of 2020. Since then, the organization has partnered with religious leaders, health experts, and community organizations nationwide to push COVID-19 education, testing, and vaccination through Black religious organizations. Quest for Health Equity also worked to help Puerto Ricans with Long COVID, establishing the island’s first clinic focused specifically on Long COVID, helping more than 2,400 patients since opening in 2021.

  • 10212022
    Fierce Biotech

    Though countless diagnostic developers struck it rich at the height of the COVID-19 pandemic, many of those that were relatively new to the testmaking game are now struggling to make up for lost sales as the spread of the virus slows down. Not so for established testing giants like Quest Diagnostics, which has seen its base business rebound in direct relation to dropping COVID-related earnings.

  • 10202022
    Associated Press

    Stocks that traded heavily or had substantial price changes Thursday: Tesla Inc., down $14.76 to $207.28. The electric vehicle maker warned it could miss its target of 50% annual growth in deliveries this year. Quest Diagnostics Inc., up $8 to $134.66. The medical laboratory chain’s third-quarter earnings and revenue beat analysts’ forecasts.

  • 10182022
    Applied Clinical Trials

    Decode Health has announced a new phase of its collaboration with Quest Diagnostics. In earlier phases of the collaboration, the two parties developed RNA (transcriptome) sequencing capabilities.

  • 10172022
    PR News

    Recent research shows more messaging about cancer screening is needed. This is because diagnoses of prostate and breast cancer remain significantly below pre-pandemic levels. While this may sound like good news, it's not. The lower figures are due to a reverberating trend stemming from the pandemic. Based on data from 1.1 million patients, a Quest Diagnostics' analysis found cancer diagnoses plummeted nearly 30% in the first months of the pandemic in 2020, when much of society and healthcare were shuttered.

  • 10132022
    ROI-NJ

    Quest Diagnostics said it recently joined forces with a free H.O.P.E. Clinic in Plainfield operated by Rutgers University to help reduce health disparities in a community with a high percentage of uninsured adults by providing free lab services. Not only is this helping people with chronic conditions receive the treatments they need, but it also is helping to keep health care costs down by giving people an alternative to emergency departments.

  • 10112022
    Chief Executive

    Recent research suggests a mainstay of HR strategy—benefits, particularly those related to employee healthcare—is underrecognized for its potential to influence recruitment and retention. According to the 2022 Health at Work report from Quest Diagnostics, workers at companies with 1,000 or more employees say the quality of a company’s benefits for physical and mental health largely defines its attractiveness as an employer of choice. When asked to cite the top two factors for attracting and retaining workers, half (50%) cited comprehensive health insurance, making it the highest rated factor. And this makes sense given how expensive, complex and critical healthcare is for employees in the U.S.

  • 10112022
    Katie Couric Media

    Alarming: A new study from Quest Diagnostics has found that cancer diagnosis dropped 11.2% below pre-pandemic levels between April 2021 and March 2022, and breast cancer diagnosis fell even further, by 17%. This suggests that women are still delaying mammograms, meaning thousands could be living with undiagnosed breast cancer. Here's when you should get your first mammogram.

Show 5102550100 per page